These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

558 related items for PubMed ID: 33872587

  • 1. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, Smith SG, Martin N, Mayer B, Yancey SW, Sousa AR, Chan R, Hopkins C, SYNAPSE study investigators.
    Lancet Respir Med; 2021 Oct; 9(10):1141-1153. PubMed ID: 33872587
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
    Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, Mullol J, Greos LS, Bosso JV, Laidlaw TM, Cervin AU, Maspero JF, Hopkins C, Olze H, Canonica GW, Paggiaro P, Cho SH, Fokkens WJ, Fujieda S, Zhang M, Lu X, Fan C, Draikiwicz S, Kamat SA, Khan A, Pirozzi G, Patel N, Graham NMH, Ruddy M, Staudinger H, Weinreich D, Stahl N, Yancopoulos GD, Mannent LP.
    Lancet; 2019 Nov 02; 394(10209):1638-1650. PubMed ID: 31543428
    [Abstract] [Full Text] [Related]

  • 3. Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study.
    Fokkens W, Trigg A, Lee SE, Chan RH, Diamant Z, Hopkins C, Howarth P, Lund V, Mayer B, Sousa AR, Yancey S, Tabberer M, SYNAPSE study group.
    J Patient Rep Outcomes; 2023 Jan 20; 7(1):4. PubMed ID: 36662344
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A.
    Lancet Respir Med; 2017 May 20; 5(5):390-400. PubMed ID: 28395936
    [Abstract] [Full Text] [Related]

  • 5. Biologics for chronic rhinosinusitis.
    Chong LY, Piromchai P, Sharp S, Snidvongs K, Philpott C, Hopkins C, Burton MJ.
    Cochrane Database Syst Rev; 2020 Feb 27; 2(2):CD013513. PubMed ID: 32102112
    [Abstract] [Full Text] [Related]

  • 6. Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count.
    Bachert C, Sousa AR, Han JK, Schlosser RJ, Sowerby LJ, Hopkins C, Maspero JF, Smith SG, Kante O, Karidi-Andrioti DE, Mayer B, Chan RH, Yancey SW, Chaker AM.
    J Allergy Clin Immunol; 2022 May 27; 149(5):1711-1721.e6. PubMed ID: 35007624
    [Abstract] [Full Text] [Related]

  • 7. Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps.
    Chupp G, Alobid I, Lugogo NL, Kariyawasam HH, Bourdin A, Chaker AM, Smith SG, Sousa AR, Mayer B, Chan RH, Matucci A.
    J Allergy Clin Immunol Pract; 2023 Nov 27; 11(11):3504-3512.e2. PubMed ID: 37586475
    [Abstract] [Full Text] [Related]

  • 8. Mepolizumab in CRSwNP/ECRS and NP: the phase III randomised MERIT trial in Japan, China, and Russia.
    Fujieda S, Wang C, Yoshikawa M, Asako M, Suzaki I, Bachert C, Han JK, Fuller A, Baylis L, Su L, Sasaki E, Sousa AR, Chan R, Zhang L.
    Rhinology; 2024 Oct 01; 62(5):576-589. PubMed ID: 39058315
    [Abstract] [Full Text] [Related]

  • 9. Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial.
    Bachert C, Sousa AR, Lund VJ, Scadding GK, Gevaert P, Nasser S, Durham SR, Cornet ME, Kariyawasam HH, Gilbert J, Austin D, Maxwell AC, Marshall RP, Fokkens WJ.
    J Allergy Clin Immunol; 2017 Oct 01; 140(4):1024-1031.e14. PubMed ID: 28687232
    [Abstract] [Full Text] [Related]

  • 10. Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24-week treatment-free follow-up.
    Desrosiers M, Diamant Z, Castelnuovo P, Hellings PW, Han JK, Peters AT, Silver J, Smith SG, Fuller A, Sousa AR, Chan RH, Gevaert P, SYNAPSE study investigators.
    Int Forum Allergy Rhinol; 2024 Jan 01; 14(1):18-31. PubMed ID: 37345861
    [Abstract] [Full Text] [Related]

  • 11. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): In-depth sinus surgery analysis.
    Fokkens WJ, Mullol J, Kennedy D, Philpott C, Seccia V, Kern RC, Coste A, Sousa AR, Howarth PH, Benson VS, Mayer B, Yancey SW, Chan R, Gane SB.
    Allergy; 2023 Mar 01; 78(3):812-821. PubMed ID: 35822924
    [Abstract] [Full Text] [Related]

  • 12. Mepolizumab improves sense of smell in severe chronic rhinosinusitis with nasal polyps: SYNAPSE.
    Mullol J, Lund VJ, Wagenmann M, Han JK, Sousa AN, Smith SG, Mayer B, Chan RH, Fokkens WJ.
    Rhinology; 2024 Jun 01; 62(3):320-329. PubMed ID: 38217844
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): a multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial.
    Zhang Y, Yan B, Shen S, Song X, Jiang Y, Shi L, Zhao C, Yang Y, Jiang L, Li J, Ye J, Liu J, Wan L, Yang Y, Chen J, Liu F, Su L, Xu Y, Tan G, Yu S, Zhang Y, Wang L, Liu S, Yan H, Liu W, Chen B, Wang C, Zhang L.
    EClinicalMedicine; 2023 Jul 01; 61():102076. PubMed ID: 37483544
    [Abstract] [Full Text] [Related]

  • 14. Evaluating treatment response to mepolizumab in patients with severe CRSwNP.
    Hopkins C, Han JK, Lund VJ, Bachert C, Fokkens WJ, Diamant Z, Mullol J, Sousa AR, Smith SG, Yang S, Mayer B, Yancey SW, Chan RH, Lee SE.
    Rhinology; 2023 Apr 01; 61(2):108-117. PubMed ID: 36716382
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.
    François B, Jafri HS, Chastre J, Sánchez-García M, Eggimann P, Dequin PF, Huberlant V, Viña Soria L, Boulain T, Bretonnière C, Pugin J, Trenado J, Hernandez Padilla AC, Ali O, Shoemaker K, Ren P, Coenjaerts FE, Ruzin A, Barraud O, Timbermont L, Lammens C, Pierre V, Wu Y, Vignaud J, Colbert S, Bellamy T, Esser MT, Dubovsky F, Bonten MJ, Goossens H, Laterre PF, COMBACTE Consortium and the SAATELLITE Study Group.
    Lancet Infect Dis; 2021 Sep 01; 21(9):1313-1323. PubMed ID: 33894131
    [Abstract] [Full Text] [Related]

  • 16. Mometasone furoate nasal spray in the treatment of nasal polyposis in Chinese patients: a double-blind, randomized, placebo-controlled trial.
    Zhou B, He G, Liang J, Cheng L, Mehta A, Liu S, Yu W, Wang Z, Han D.
    Int Forum Allergy Rhinol; 2016 Jan 01; 6(1):88-94. PubMed ID: 26575524
    [Abstract] [Full Text] [Related]

  • 17. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis.
    Bachert C, Hellings PW, Mullol J, Hamilos DL, Gevaert P, Naclerio RM, Joish VN, Chao J, Mannent LP, Amin N, Abbe A, Taniou C, Fan C, Pirozzi G, Graham NMH, Mahajan P, Staudinger H, Khan A.
    Allergy; 2020 Jan 01; 75(1):148-157. PubMed ID: 31306495
    [Abstract] [Full Text] [Related]

  • 18. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
    Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P.
    Lancet; 2012 Aug 18; 380(9842):651-9. PubMed ID: 22901886
    [Abstract] [Full Text] [Related]

  • 19. NAVIGATE I: Randomized, Placebo-Controlled, Double-Blind Trial of the Exhalation Delivery System With Fluticasone for Chronic Rhinosinusitis With Nasal Polyps.
    Sindwani R, Han JK, Soteres DF, Messina JC, Carothers JL, Mahmoud RA, Djupesland PG.
    Am J Rhinol Allergy; 2019 Jan 18; 33(1):69-82. PubMed ID: 30477309
    [Abstract] [Full Text] [Related]

  • 20. Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial.
    Jackson DJ, Bacharier LB, Gergen PJ, Gagalis L, Calatroni A, Wellford S, Gill MA, Stokes J, Liu AH, Gruchalla RS, Cohen RT, Makhija M, Khurana Hershey GK, O'Connor GT, Pongracic JA, Sherenian MG, Rivera-Spoljaric K, Zoratti EM, Teach SJ, Kattan M, Dutmer CM, Kim H, Lamm C, Sheehan WJ, Segnitz RM, Dill-McFarland KA, Visness CM, Becker PM, Gern JE, Sorkness CA, Busse WW, Altman MC, US National Institute of Allergy and Infectious Disease's Inner City Asthma Consortium.
    Lancet; 2022 Aug 13; 400(10351):502-511. PubMed ID: 35964610
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.